Beta-thalassemia syndromes, clinical and laboratory approach

Emine Türkkan, Su Gülsün Berrak, Cengiz Canpolat

Research output: Contribution to journalArticle

Abstract

The Beta (β) thalassemia syndromes are a heterogeneous group of genetic disorders. The frequency of thalassemia is dependent on the ethnic origins of the patient population. Turkey is located in a geographic area of the world where thalassemia syndromes are common. The incidence rate of β-thalassemia carriers was stated to be 2 per cent in Turkey. Clinical manifestations are diverse and range from asymptomatic hypochromia and microcytosis to profound anemia leading to death in early childhood if untreated. Individuals who are homozygous for the β-thalassemia genes have severe, transfusion-dependent anemia and are said to have β-thalassemia major. Thalassemia intermedia is a condition in which the degree of hemolysis is milder even though the patient may have a deficiency of both β genes. Therefore, thalassemia intermedia is essentially a descriptive term that refers to minimal or no need for transfusions. The presence of one normal gene in the heterozygotes usually leads to enough normal β-globin chain synthesis so that the affected individuals are usually asymptomatic with only a mild anemia. This condition is referred to as β-thalassemia minor or β-thalassemia trait. In this report clinical and laboratory findings of βthalassemia syndromes in childhood are reviewed.

Original languageEnglish (US)
Pages (from-to)194-200
Number of pages7
JournalMarmara Medical Journal
Volume15
Issue number3
StatePublished - Jul 2002
Externally publishedYes

Fingerprint

Thalassemia
beta-Thalassemia
Anemia
Turkey
Genes
Inborn Genetic Diseases
Globins
Heterozygote
Hemolysis
Incidence
Population

Keywords

  • Anemia
  • Beta thalassemia
  • Childhood
  • Hypocromic microcytic anemia

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Türkkan, E., Berrak, S. G., & Canpolat, C. (2002). Beta-thalassemia syndromes, clinical and laboratory approach. Marmara Medical Journal, 15(3), 194-200.

Beta-thalassemia syndromes, clinical and laboratory approach. / Türkkan, Emine; Berrak, Su Gülsün; Canpolat, Cengiz.

In: Marmara Medical Journal, Vol. 15, No. 3, 07.2002, p. 194-200.

Research output: Contribution to journalArticle

Türkkan, E, Berrak, SG & Canpolat, C 2002, 'Beta-thalassemia syndromes, clinical and laboratory approach', Marmara Medical Journal, vol. 15, no. 3, pp. 194-200.
Türkkan E, Berrak SG, Canpolat C. Beta-thalassemia syndromes, clinical and laboratory approach. Marmara Medical Journal. 2002 Jul;15(3):194-200.
Türkkan, Emine ; Berrak, Su Gülsün ; Canpolat, Cengiz. / Beta-thalassemia syndromes, clinical and laboratory approach. In: Marmara Medical Journal. 2002 ; Vol. 15, No. 3. pp. 194-200.
@article{c37cd2e9fcc24b1a9a73f1585ee77f0d,
title = "Beta-thalassemia syndromes, clinical and laboratory approach",
abstract = "The Beta (β) thalassemia syndromes are a heterogeneous group of genetic disorders. The frequency of thalassemia is dependent on the ethnic origins of the patient population. Turkey is located in a geographic area of the world where thalassemia syndromes are common. The incidence rate of β-thalassemia carriers was stated to be 2 per cent in Turkey. Clinical manifestations are diverse and range from asymptomatic hypochromia and microcytosis to profound anemia leading to death in early childhood if untreated. Individuals who are homozygous for the β-thalassemia genes have severe, transfusion-dependent anemia and are said to have β-thalassemia major. Thalassemia intermedia is a condition in which the degree of hemolysis is milder even though the patient may have a deficiency of both β genes. Therefore, thalassemia intermedia is essentially a descriptive term that refers to minimal or no need for transfusions. The presence of one normal gene in the heterozygotes usually leads to enough normal β-globin chain synthesis so that the affected individuals are usually asymptomatic with only a mild anemia. This condition is referred to as β-thalassemia minor or β-thalassemia trait. In this report clinical and laboratory findings of βthalassemia syndromes in childhood are reviewed.",
keywords = "Anemia, Beta thalassemia, Childhood, Hypocromic microcytic anemia",
author = "Emine T{\"u}rkkan and Berrak, {Su G{\"u}ls{\"u}n} and Cengiz Canpolat",
year = "2002",
month = "7",
language = "English (US)",
volume = "15",
pages = "194--200",
journal = "Marmara Medical Journal",
issn = "1019-1941",
publisher = "Marmara University",
number = "3",

}

TY - JOUR

T1 - Beta-thalassemia syndromes, clinical and laboratory approach

AU - Türkkan, Emine

AU - Berrak, Su Gülsün

AU - Canpolat, Cengiz

PY - 2002/7

Y1 - 2002/7

N2 - The Beta (β) thalassemia syndromes are a heterogeneous group of genetic disorders. The frequency of thalassemia is dependent on the ethnic origins of the patient population. Turkey is located in a geographic area of the world where thalassemia syndromes are common. The incidence rate of β-thalassemia carriers was stated to be 2 per cent in Turkey. Clinical manifestations are diverse and range from asymptomatic hypochromia and microcytosis to profound anemia leading to death in early childhood if untreated. Individuals who are homozygous for the β-thalassemia genes have severe, transfusion-dependent anemia and are said to have β-thalassemia major. Thalassemia intermedia is a condition in which the degree of hemolysis is milder even though the patient may have a deficiency of both β genes. Therefore, thalassemia intermedia is essentially a descriptive term that refers to minimal or no need for transfusions. The presence of one normal gene in the heterozygotes usually leads to enough normal β-globin chain synthesis so that the affected individuals are usually asymptomatic with only a mild anemia. This condition is referred to as β-thalassemia minor or β-thalassemia trait. In this report clinical and laboratory findings of βthalassemia syndromes in childhood are reviewed.

AB - The Beta (β) thalassemia syndromes are a heterogeneous group of genetic disorders. The frequency of thalassemia is dependent on the ethnic origins of the patient population. Turkey is located in a geographic area of the world where thalassemia syndromes are common. The incidence rate of β-thalassemia carriers was stated to be 2 per cent in Turkey. Clinical manifestations are diverse and range from asymptomatic hypochromia and microcytosis to profound anemia leading to death in early childhood if untreated. Individuals who are homozygous for the β-thalassemia genes have severe, transfusion-dependent anemia and are said to have β-thalassemia major. Thalassemia intermedia is a condition in which the degree of hemolysis is milder even though the patient may have a deficiency of both β genes. Therefore, thalassemia intermedia is essentially a descriptive term that refers to minimal or no need for transfusions. The presence of one normal gene in the heterozygotes usually leads to enough normal β-globin chain synthesis so that the affected individuals are usually asymptomatic with only a mild anemia. This condition is referred to as β-thalassemia minor or β-thalassemia trait. In this report clinical and laboratory findings of βthalassemia syndromes in childhood are reviewed.

KW - Anemia

KW - Beta thalassemia

KW - Childhood

KW - Hypocromic microcytic anemia

UR - http://www.scopus.com/inward/record.url?scp=0037570881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037570881&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0037570881

VL - 15

SP - 194

EP - 200

JO - Marmara Medical Journal

JF - Marmara Medical Journal

SN - 1019-1941

IS - 3

ER -